Ascendis Pharma AS (ASND)

124.27 -1.76 (-1.40%) USD  |  NASDAQ  |  Nov 14, 16:00
118.46 -5.81 (-4.68%) After-Hours: 20:00
More

Ascendis Pharma Research and Development Expense (Quarterly): 89.88M for June 30, 2024

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2013. Upgrade now.
Date Value
June 30, 2024 89.88M
March 31, 2024 76.78M
December 31, 2023 97.87M
September 30, 2023 121.33M
June 30, 2023 114.52M
March 31, 2023 113.97M
December 31, 2022 111.06M
September 30, 2022 98.15M
June 30, 2022 96.27M
March 31, 2022 93.35M
December 31, 2021 75.09M
September 30, 2021 69.28M
June 30, 2021 100.40M
March 31, 2021 106.22M
December 31, 2020 90.32M
September 30, 2020 74.91M
June 30, 2020 70.02M
March 31, 2020 63.47M
December 31, 2019 55.67M
September 30, 2019 51.44M
June 30, 2019 49.23M
March 31, 2019 58.23M
Date Value
December 31, 2018 43.35M
September 30, 2018 36.64M
June 30, 2018 48.04M
March 31, 2018 37.52M
December 31, 2017 33.01M
September 30, 2017 34.17M
June 30, 2017 24.07M
March 31, 2017 21.95M
December 31, 2016 21.57M
September 30, 2016 18.43M
June 30, 2016 15.00M
March 31, 2016 17.92M
December 31, 2015 13.69M
September 30, 2015 8.933M
June 30, 2015 13.97M
March 31, 2015 8.275M
December 31, 2014 9.393M
September 30, 2014 5.211M
June 30, 2014 6.427M
March 31, 2014 4.876M
December 31, 2013 3.711M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

55.67M
Minimum
Dec 2019
121.33M
Maximum
Sep 2023
90.45M
Average
93.35M
Median
Mar 2022

Research and Development Expense (Quarterly) Benchmarks

Novo Nordisk AS 1.398B
Evaxion Biotech AS 2.614M
Biodexa Pharmaceuticals PLC --
NuCana PLC 8.540M
Genfit SA --